Tag: Alzheimer’s

Washington University School of Medicine Developed Test to Detect Alzheimer’s Disease

Researchers at Washington University School of Medicine in St. Louis developed the test to detect early brain changes such as memory loss and confusion. The blood test is able to measure levels of the...

Amgen and Novartis to Stop Alzheimer’s Prevention Study

Amgen, Novartis and Banner Alzheimer's Institute have announced the collective decision to discontinue investigation of the BACE1 inhibitor CNP520 (umibecestat) in two pivotal Phase 2/3 studies in the...

Eisai and Allm will Look for Digital Health Solutions

Eisai Co., Ltd. and Allm Inc. announced that they have entered into a capital and business alliance agreement for ICT digital health solutions in various areas as well as regional medical treatment an...

Eisai Appoints New Execs to Boost Alzheimer’s team

Following the high-profile failure of what was to be a successful Alzheimer’s disease drug, one of the companies behind it has appointed two executives to bolster its AD business.  Japanese drugmaker ...

Biogen Said It Will Continue to Work on Alzheimer’s Despite Failed Trials

biogen
Biogen said it will continue to work on Alzheimer’s but will reduce its risk by diversifying its pipeline and approach. Biogen Inc. executives sought on Wednesday to ease investors’ concerns over t...

Concert Pharma Announced the Initiation of Early-Stage Schizophrenia Study

Concert Pharmaceuticals, Inc. CNCE announced that it has initiated a multiple-ascending dose ("MAD") phase I study on its pipeline candidate, CTP-692 (a novel deuterium-modified form of D-serine), as ...

Biogen and Eisai Stop Trials of Alzheimer’s Treatment

Biogen and Eisai, Co., Ltd. (Tokyo, Japan) announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE, designed to evaluate the efficacy and safety of aducanumab in patients wi...

Young Russian Scientist Invited New Alzheimer’s Diagnostic Way

Alzheimer's disease is a neurological disorder in which the death of brain cells causes memory loss and cognitive decline. A special device with artificial intelligence able to predict it has been inv...

Zydus Cadila Announced First Approval for Transdermal Product in US

Zydus Cadila has received the approval from the USFDA to market Rivastigmine Transdermal System (US RLD – EXELON® PATCH), 4.6 mg/24 hrs, 9.5 mg/24 hrs and 13.3 mg/24 hrs, marking its first approval fo...

FDA Warns 17 Companies for Selling Nonapproved Medicine

The U.S. Food and Drug Administration today posted 12 warning letters and 5 online advisory letters issued to foreign and domestic companies that are illegally selling more than 58 products, many that...

Roche and AC Immune Stop Trials of Alzheimer’s Drug

Roche and AC Immune have discontinued phase III trials of their Alzheimer’s disease drug crenezumab after an interim analysis indicated it would not hit its primary endpoint. Crenezumab is an anti-...

Generic for Alzheimer’s and Parkinson’s Approved by FDA

The U.S. Food and Drug Administration (FDA) approved Bridgewater, NJ-based Amneal Pharmaceuticals’ generic version of Novartis’ Exelon Patch (Rivastigmine Transdermal System) for dementia related to A...

Biogen to Expand CNS Pipeline

Biogen has signed a brace of collaborations to expand its central nervous system (CNS) pipeline, adding new candidates for Alzheimer’s, multiple sclerosis and other neurological diseases. The first...

Lilly and AC Immune to Develop Tau-Targeting Alzheimer’s Drug

Eli Lilly has paid $81m to develop drugs targeting aggregation of tau proteins associated with Alzheimer’s with Swiss biotech AC Immune, as focus shifts away from therapies targeting clumps of amyloid...

CarThera to Develop Ultrasound-Based Devices to Treat Brain Bisorders

French company CarThera has raised €9 million in its Series B funding round to help it develop ultrasound-based medical devices to treat brain disorders and overcome the challenges of the blood-brain ...

New Alzheimer’s cure to enter clinical trials

The first drug candidate from Eisai and University College London (UCL)’s drug discovery collaboration is to enter Phase I clinical trials for Alzheimer’s disease (AD) early next year. The candidat...